Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), primarily used as an antidiabetic and anti-obesity agent, which manifests pleiotropic effects through activation of GLP-1 receptors. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.